rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains

Antimicrob Agents Chemother. 2012 May;56(5):2743-5. doi: 10.1128/AAC.06227-11. Epub 2012 Feb 27.

Abstract

The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology*
  • Antitubercular Agents / pharmacology*
  • DNA, Bacterial / genetics
  • Drug Resistance, Bacterial / genetics
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Mutation*
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics*
  • Mycobacterium tuberculosis / isolation & purification
  • Oxazolidinones / pharmacology*
  • Ribosomal Protein L3
  • Ribosomal Proteins / genetics*

Substances

  • Acetamides
  • Antitubercular Agents
  • DNA, Bacterial
  • Oxazolidinones
  • Ribosomal Protein L3
  • Ribosomal Proteins
  • Linezolid